European Society of Cardiology

New 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure released

New England Journal of Medicine

EMPEROR-PRESERVED demonstrates empagliflozin significantly reduces the risk of HF hospitalization in patients with HFpEF

New England Journal of Medicine

Pooled analysis from EMPEROR-Preserved and EMPEROR-Reduced show that the HF benefit with empagliflozin was consistent across two trials, with important differences in renal outcomes

JAMA Cardiology

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children

New England Journal of Medicine

FIGARO-DKD trial shows that finerenone has salutary effects on CV outcomes among patients with T2DM and CKD

European Society of Cardiology

FIDELITY analysis suggests that finerenone benefits patients with diabetes across spectrum of kidney disease

You still have a chance to present your research at the upcoming 16th Annual Cardiometabolic Health Congress! The deadline for abstract submissions is now September 3, 2021. Act now to have your poster presented to the foremost leaders in the field—and for a chance to win the CMHC Best Poster Award!

Featured Podcast

Hear Dr. Harold Bays, Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center as well as Your Body Goal in Louisville, KY., and Chief Science Officer of Obesity Medicine Association share his insight on obesity pharmacotherapy, cardiometabolic consequences of obesity as well as how the COVID-19 pandemic impacts obesity management.

Podcast Also Available On:

Faculty in the News

CMHC Senior Planning Committee Member, Dr. Deepak L. Bhatt, recently presented new data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack who are at risk for major adverse cardiovascular events.

Read more.